H1 2018 Pipeline Review for Gallbladder Cancer - ResearchAndMarkets.com

June 5, 2018

DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Gallbladder Cancer - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

Gallbladder Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 17, 5 and 2 respectively.

Companies Mentioned

4SC AG Advenchen Laboratories LLC Array BioPharma Inc Aslan Pharmaceuticals Pte Ltd Bayer AG BeiGene Ltd Eli Lilly and Co Halozyme Therapeutics Inc Hutchison MediPharma Ltd Ipsen SA Jiangsu Hengrui Medicine Co Ltd Kringl

Key Topics Covered

Introduction Gallbladder Cancer - Overview Gallbladder Cancer - Therapeutics Development Gallbladder Cancer - Therapeutics Assessment Gallbladder Cancer - Companies Involved in Therapeutics Development Gallbladder Cancer - Drug Profiles Gallbladder Cancer - Dormant Projects Gallbladder Cancer - Discontinued Products Appendix

For more information about this report visit https://www.researchandmarkets.com/research/qm5wql/h1_2018_pipeline?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006474/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 01:44 PM/DISC: 06/05/2018 01:44 PM


Update hourly